Background: There are some reports showing the susceptibility of some strains of Acinetobacter baumannii to the b-lactamase inhibitor clavulanic acid. To address this issue, we determined the MIC of clavulanic acid for a broad collection of Acinetobacter spp. isolates collected in a multicentre study. In addition, we showed the consequences of this susceptibility to yield false extended-spectrum b-lactamase (ESBL) detection in this genus.
Introduction
Acinetobacter spp. are opportunistic pathogens with increasing relevance in nosocomial infections.
1 They can be associated with a wide range of clinical complications, such as pneumonia, septicaemia, urinary tract infections, wound infections and meningitis, especially in immunocompromised patients. 2 Antimicrobial treatment of these clinical infections, particularly those caused by Acinetobacter baumannii, may be compromised by multiple resistances to antibiotics. 3 -12 To treat infections caused by A. baumannii isolates, the use of the b-lactamase inhibitor sulbactam with or without ampicillin has provided good results, 13 especially with multiresistant A. baumannii strains. 6 While A. baumannii is highly susceptible to sulbactam, it is less susceptible to other b-lactamase inhibitors, such as clavulanic acid and tazobactam. 14 Additionally, polymyxin B remains active against multiresistant strains of A. baumannii. 15 Among A. baumannii strains, resistance to b-lactams is often mediated by a naturally occurring AmpC-type cephalosporinase, which may confer a noticeable resistance when overexpressed. 7 In addition, TEM-1, TEM-2, CARB-5, PER-type, CTX-M-type, VEB-1, OXA derivatives and several metalloenzymes have been found in A. baumannii. 3,6,8,12,16 -19 Among Acinetobacter genomic species 3 (AG3), only VIM-2 and IMP-4 have been detected 19 in addition to the class C chromosomal cephalosporinase. 4 Also, the poor outer membrane permeability (OMP) of A. baumannii and PBP alterations are implicated in b-lactam resistance. 6,9,20 -23 Currently there is a relative paucity of data regarding the effectiveness of in vitro antibiotic susceptibility testing methods for Acinetobacter spp. 24 A similar situation may be considered regarding extended-spectrum b-lactamase (ESBL) detection in Acinetobacter spp. CLSI only report criteria to detect ESBL in Escherichia coli, Klebsiella spp. and Proteus mirabilis. In addition, some guidelines raise the question of ESBL detection in Acinetobacter spp. as ESBLs are not the main cause of cephalosporin resistance in this genus and should be sought routinely.
This study aimed to assess the susceptibility of a broad collection of Acinetobacter spp. isolated from a multicentre study from 28 different hospitals of Spain to clavulanic acid, and to show how susceptibility to clavulanic acid relates to a false ESBL detection phenotype in this genus.
Materials and methods

Bacterial strains
In November 2000, all phenotypically and preliminary identified A. baumannii isolates from clinical samples were collected from 28 hospitals in Spain, as a part of a nationwide multicentre study.
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A total of 244 strains of Acinetobacter spp. were collected: 226 A. baumannii, 15 AG3 and 3 unidentified Acinetobacter strains. These species were identified by amplified ribosomal DNA restriction analysis (ARDRA) 26 and sequencing of nucleotides of 16S rRNA.
Clinical strains of A. baumannii producing PER-1 and CTX-M-2 were used as ESBL-positive controls in the experiments.
Antibiotic susceptibility tests and screening of b-lactamases (ESBLs)
Antibiotic susceptibility profiles were determined by microdilution following CLSI criteria. 27 As no breakpoints for clavulanic acid are available, we arbitrarily established three categories of susceptibility: 16, 32 -128 and 256 mg/L.
The compounds tested were: cefotaxime, ceftazidime and piperacillin (Sigma-Aldrich, Madrid, Spain), cefepime (BristolMyers Squibb Co., Wallingford, CT, USA), clavulanic acid (GlaxoSmithKline, Madrid, Spain) and sulbactam (Pfizer Inc., Central Research Division, Sandwich, UK). The range of clavulanic acid concentrations for MIC analysis was 1-512 mg/L.
ESBL detection was performed using the following methods. for Enterobacteriaceae, a 5 mm increase in a zone diameter for every cephalosporin tested in combination with clavulanic acid compared with its zone when tested alone was considered as indicative of ESBL production.
Molecular typing experiments
The epidemiological relationship of the 244 Acinetobacter isolates was determined by PFGE with SmaI following the method of Gautom 30 and confirmed by repetitive extragenic palindromic (REP)-PCR 31 as previously described.
Isoelectric focusing (IEF) assay and b-lactam hydrolysis b-Lactamases were characterized by IEF of ultrasonic bacterial extracts as previously reported. 32 The same bacterial extracts from the Acinetobacter isolates yielding an ESBL-positive test were analysed by spectrophotometry for cefotaxime and ceftazidime hydrolysis with and without 4 mg/L clavulanic acid as previously described. 7 
b-Lactamase identification
Several primer pairs hybridized with previously reported b-lactamase genes were used in an amplification reaction to detect some b-lactamase genes. The primer pairs used were AMPC1 5 0 -ATGCGATTTAAAAAAATTTC and AMPC2 5 0 -TTATTTCTTTAT TGCATTC as well as AMPC3 5 0 -ACTTACTTCAACTCGCGA CG and AMPC4 5 0 -AATTACTGTCTAATAAAGTTT, which amplify the cephalosporinase ampC gene from AG3 and A. baumannii, respectively. 4, 7 Chromosomal DNA from Acinetobacter spp. isolates was purified according to standard protocols (MasterPure DNA purification kit; Epicenter, Madison, WI, USA). Five hundred nanograms of the Acinetobacter spp. chromosomes were used as templates to be amplified by PCR with the two primer pairs: AMPC1/AMPC2 and AMPC3/AMPC4. The PCR was performed under the following conditions: denaturation, 10 min at 948C; amplification, 30 cycles of 1 min at 948C, 1 min at 558C and 2 min at 728C; and elongation, 16 min at 728C. An aliquot (20 mL) of the sample was subjected to electrophoresis in a 1.0% agarose gel. The gel showed an amplified product, detected by ethidium bromide staining (50 mg/L), of 1150 and 550 bp with combinations AMPC1/AMPC2 and AMPC3/ AMPC4, respectively, which were the expected sizes of the ampC gene in relation to that in AG3 and A. baumannii, respectively.
Expression of AmpC cephalosporinase and RT-PCR analysis
Detection of the expression of the naturally occurring cephalosporinase AmpC enzymes in the Acinetobacter spp. isolates was carried out by comparing piperacillin and ceftazidime MICs with and without cloxacillin at 250 mg/L. Also, and with the same aim, total RNA from Acinetobacter isolates at identical exponential phase of growth was purified by TRIzol Max Bacterial RNA Isolation Kit (Invitrogen, Carlsbad, CA, USA), following the manufacturer's instructions. Two A. baumannii isolates in which an ESBL phenotype was not suggested by Etest or any phenotypic method were used as controls.
AmpC expression of Acinetobacter spp. isolates was monitored in a semi-quantitative manner by RT-PCR (Promega, Madison, WI, USA), following the manufacturer's instructions.
To semi-quantify AmpC expression, the transcription of the gyrA gene was analysed and used as an internal control. Band intensity was compared between the ampC and gyrA amplicons. The oligonucleotides used to retrotranscribe and amplify ampC and gyrA genes were as follows: AMPCfor 5 0 -ACTTACTTCAACTCGCGACG and AMPC2rev 5 0 -AATTACTGTCTAATAAAGTTT; and GYRAfor 5 0 -AATCTGCCCGTGTCGTTG and GYRArev 5 0 -GCCATACCT ACGGCGA. Aliquots (10 mL) taken at 17, 20 and 23 cycles of the amplification procedure were subjected to electrophoresis in a 1.0% agarose gel. The gel showed two amplified products, detected by ethidium bromide staining (50 mg/L), of 550 and 350 bp, which were the expected sizes of the ampC and gyrA genes, respectively, in relation to those in A. baumannii.
Purification of AmpC enzymes
The ampC gene (GenBank accession no. AM283527) of a representative clavulanic acid-susceptible Acinetobacter (strain 65 in Tables 2 and 3 ) was cloned into the expression vector pGEX-6P-1, which allows a fusion protein between glutathione S-transferase (GST) and the AmpC enzyme. The b-lactamase was purified to homogeneity with the GST gene fusion system (Amersham Pharmacia Biotech, Europe GmbH) according to the manufacturer's directions. IC 50 values were determined as described previously.
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Results
Genotypes and clavulanic acid susceptibility Table 2) . A microdilution assay was performed with the 15 clinical strains of Acinetobacter spp. as well as with A. baumannii controls (Table 2) . Clear synergy was observed among the group of isolates that were susceptible to clavulanic acid (more than three doubling concentration dilutions reduction in the presence of the inhibitor in most of the isolates). Synergy was more pronounced with cefotaxime and ceftazidime. In contrast, no synergy was detected with clavulanic acid-intermediate or -resistant isolates (Table 2) . A. baumannii positive control isolates producing CTX-M-2 and PER-1 showed clear synergy, which was more evident with cefotaxime (CTX-M-2), and ceftazidime and cefepime (PER-1), respectively.
The same 15 Acinetobacter isolates were studied for ESBL detection by the double disc diffusion method with cefotaxime, ceftazidime and cefepime discs at three different distances from the centre of a disc containing 10 mg of clavulanic acid (Figure 1a) . None of the cephalosporins and clavulanic acid combinations showed apparent synergy against Acinetobacter spp. isolates. On the contrary, synergy (mainly with cefepime) was obtained with the ESBL-positive A. baumannii controls.
Also, we tested whether or not the combined disc method was able to detect ESBL production in the Acinetobacter spp. isolates. For this, the diameters of zones of inhibition of cephalosporins with and without 10 mg of clavulanic acid were measured in these isolates and two A. baumannii ESBL-positive False ESBL detection in Acinetobacter spp controls ( Figure 1b and Table 3 ). The results showed that whereas the isolates included in the clavulanic acid-susceptible group (isolates 11, 34, 65, 73 and 91) showed some degree of synergy in the presence of cephalosporin plus clavulanic acid (in some cases and with specific antibiotics higher than 5 mm in the presence of clavulanic acid and mainly due to its intrinsic clavulanic acid susceptibility), the remaining intermediate and resistant Acinetobacter isolates did not show any synergy in the combined disc method tests (no more than 1-2 mm inhibition zone difference in the presence of clavulanic acid). The A. baumannii ESBL-positive controls showed clear synergy (the exception is CTX-M-2 with ceftazidime for its lower hydrolytic activity towards this antibiotic). Lastly, we attempted to determine whether Etests for ESBL detection in Enterobacteriaceae can detect ESBL activity in Acinetobacter spp. and the impact of clavulanic acid susceptibility in the Etest analysis. With this aim, the same 15 Acinetobacter isolates were studied for ESBL detection with the above mentioned Etest strips. Those isolates included in the clavulanic acid-susceptible group (isolates 11, 34, 65, 73 and 91) yielded a positive test for ESBL production (Figure 1c) . Those Acinetobacter isolates that were intermediate or resistant to clavulanic acid (MICs 16 to .256 mg/L) yielded a negative ESBL Etest result. The ESBL-producing positive control Acinetobacter isolates were also negative for ESBL activity by Etest.
b-Lactamase identification and analysis
To elucidate the number of b-lactamases produced by each of the 15 isolates, protein extracts were analysed by IEF, as described in the Materials and methods section. The 15 Acinetobacter spp. isolates yielded a unique band of pI . 9.0. This strongly suggested the presence of the previously reported chromosomal cephalosporinase 4, 7 that corresponded to the chromosomal ampC gene of Acinetobacter, which we identified in these isolates by PCR (data not shown).
Cefotaxime and ceftazidime hydrolysis was detected by spectrophotometric analysis to different degrees using protein extracts from the 15 Acinetobacter spp. isolates. This activity was not inhibited by 4 mg/L clavulanic acid. When protein extracts from positive controls were used, some degree of inhibition was observed (data not shown). Together the data showed no ESBL production occurred in the 15 Acinetobacter spp. isolates.
AmpC expression
To explain the basis for the increased susceptibility to clavulanic acid in the Acinetobacter isolates (or genotypes) under study, we considered that if somehow the AmpC enzyme affects the amount of clavulanic acid present in the cell, a reduction in the expression of the enzyme may increase susceptibility to the b-lactamase inhibitor. To test the hypothesis that increasing clavulanic acid susceptibility may be due to underexpression of the chromosomal cephalosporinase, we used two experimental approaches:
(i) Piperacillin and ceftazidime MICs were determined with and without cloxacillin (250 mg/L) for the 15 Acinetobacter isolates. The results showed that piperacillin MICs were reduced in the presence of cloxacillin in most isolates, indicating that the isolates overexpress the AmpC enzyme and no differences were detected regardless of their susceptibility to clavulanic acid (data not shown). (ii) A RT-PCR was performed using as a source total RNA from the 15 Acinetobacter spp. isolates. PCR samples collected at 17, 20 and 23 cycles of the amplification procedure showed no difference in amplicon band intensity among all of the isolates (clavulanic acid-susceptible and -non-susceptible isolates).
We also considered whether inhibition of the AmpC enzyme by clavulanic acid may occur in response to the nucleotide sequences of the ampC genes in these isolates. The AmpC enzyme from isolate 65 (clavulanic acid MIC of 4 mg/L and false ESBL producer) was cloned, expressed and purified by affinity chromatography. Kinetic experiments revealed an IC 50 (mM) of clavulanic acid of .250, indicating non-susceptibility.
Discussion
Nosocomial outbreaks of infection by strains of A. baumannii have been reported worldwide 6, 33 and most strains are resistant to many of the antibiotics usually used in clinical practice. Sulbactam and polymyxin B drugs are sometimes the only therapeutic alternatives for the treatment of these pandrug-resistant A. baumannii isolates. 13, 15 In this study, we found that 44 out of 244 Acinetobacter clinical isolates (mostly A. baumannii and AG3) belonging to 44 different genotypes showed clavulanic acid susceptibility (MICs of 2-16 mg/L). Further, we demonstrated that this phenomenon was related to a false ESBL test result when a synergistic method between cephalosporin and clavulanic acid was tested (microdilution, combined disc and Etest). However, none of the Acinetobacter isolates with clavulanic acid susceptibility (clavulanic acid MICs 16 mg/L) showed synergy between cephalosporins and clavulanic acid when they were tested by the double disc diffusion method, thus confirming the reliability of this test for ESBL detection in Acinetobacter (A. baumannii ESBL producers tested yielded a positive result with this technique). The remaining Acinetobacter isolates (with higher clavulanic acid MICs, groups II and III) yielded a negative ESBL test result with all methods used.
We found no evidence of ESBLs in the 15 Acinetobacter spp. isolates and concluded that clavulanic acid susceptibility in the strains under study was not related to any b-lactamase (ESBL or naturally occurring AmpC enzyme). Outer membrane protein (OMP) profiles did not vary between Acinetobacter spp. isolates with different degrees of clavulanic acid susceptibility (groups I, II and III) (data not shown). MIC values for a more resistant spontaneous revertant from group I were observed in the presence of a specific efflux pump inhibitor (data not shown). No differences in MIC values were detected when the efflux pump inhibitor was added. Together the data suggest that clavulanic acid susceptibility is most likely associated with PBP alterations in these isolates.
The susceptibility of Acinetobacter spp. to clavulanic acid has been described previously. 14 Pandey et al. 34 studied 100 consecutive isolates of A. baumannii obtained from various clinical samples. They found that 11% of isolates showed an amoxicillin/clavulanic acid MIC of ,8/4 mg/L, therefore being categorized as susceptible to the antibiotic combination. Also, Sturenburg et al. 35 reported that two out of six Acinetobacter strains tested for ESBL production with MicroScan ESBL plus confirmation panel yielded a positive ESBL result although PCR analysis showed that these strains were lacking an ESBL. In another study, Higgins et al. 36 studied in vitro activities of the b-lactamase inhibitors alone or in combination with b-lactams against 115 epidemiologically characterized multidrug-resistant A. baumannii strains. They showed clavulanic acid MIC 50 and MIC 90 values of 16 and 64 mg/L. Interestingly, 40% of the strains showed clavulanic acid MIC values lower than 16 mg/L and one strain had a clavulanic acid MIC of 2 mg/L. Overall, these results may indicate that, for unknown reasons, some Acinetobacter isolates may show an increased clavulanic acid susceptibility, but not with sulbactam, and these strains may yield a false ESBL test result when they are tested by an inhibitor-based method.
The present results have clear implications for routine clinical practice in microbiology laboratories, as they suggest that manual or automatic procedures focused on inhibitory-based methods for ESBL detection may yield false results with Acinetobacter isolates. Any indication of ESBL production in Acinetobacter spp. by these methods must be confirmed by another method, e.g. double disc diffusion method or combined disc method (if a disc of clavulanic acid alone is also used) with cefepime, and by a reference laboratory. These findings will help in the monitoring of the epidemiology of infections caused by Acinetobacter spp., allowing better control of the diagnosis and detection of ESBL-producing Acinetobacter spp. isolates.
